SINOHEALTH TECH (02361) expects to increase the public shareholding ratio by no less than 8 percentage points by the end of June 2027.
Zhongkang Technology Holdings (02361) announced that, in line with the companys strategic development and the performance completion of eligible participants, the company anticipates completing the grant of currently available share awards within the next three years. The details of the plan are as follows:
SINOHEALTH TECH (02361) published an announcement stating that, in conjunction with the company's strategic development and the performance of qualified participants, the company expects to complete the granting of currently available share awards within the next three years. The plan details are as follows:
(i) As of the date of this announcement, the share awards available for granting represent 9.83% of the company's total share capital. The company will consider the achievement of operational targets for the years 2026, 2027, and 2028, as well as the comprehensive assessment results of the incentive participants, and will grant at least 2% of the companys total share capital each year to non-core connected persons of the company; and
(ii) The granting of the companys share awards will be determined based on multiple indicators of the company and the individual performance of qualified participants, aimed at incentivizing the award recipients to promote the companys medium- to long-term development, thereby maximizing the effectiveness of the share awards.
Taking into account strategic development and market conditions, the company plans to further increase its public shareholding through various channels, with specific plans including:
(a) Completing equity financing to expand the companys share capital; and/or (b) Actively communicating with major shareholders to discuss arrangements for the major shareholders to sell part of their holdings to independent third parties in order to restore the company's public shareholding.
On one hand, the company will actively seek suitable placement agents and other related service providers, while on the other hand, it will communicate with the company's major shareholders and potential investors to advance the above plans. Given the volatility of capital markets, the process of engaging with potential investors, negotiating transaction terms, and obtaining necessary approvals will take some time. The company expects that through the aforementioned plans in segments (a) and/or (b), the public shareholding will increase by no less than 8 percentage points by the end of June 2027.
Based on the overall plan for restoring public shareholding indicated in segments (i), (ii), (a), and (b), the company anticipates meeting the initial designated threshold stipulated in Listing Rule 13.32B(1) by the end of June 2027.
Related Articles

XIAOMI-W (01810) invested HKD 49.9504 million on August 6th to repurchase 1.862 million shares.

HAOHAI BIOTEC (06826) subsidiary has obtained a medical device registration certificate for its trifocal toric intraocular lens product.

HENG TAI (00197): Chan Wai Ying has been appointed as an independent non-executive director.
XIAOMI-W (01810) invested HKD 49.9504 million on August 6th to repurchase 1.862 million shares.

HAOHAI BIOTEC (06826) subsidiary has obtained a medical device registration certificate for its trifocal toric intraocular lens product.

HENG TAI (00197): Chan Wai Ying has been appointed as an independent non-executive director.

RECOMMEND





